Health officials have given a life-extending drug the green light for widespread NHS, giving hope to thousands of men facing a "death sentence" from prostate cancer.
The National Institute for Health and Care Excellence (Nice) said the drug enzalutamide, also known as xtandi, should be considered for use in the treatment of men with hormone relapsed prostate cancer that has spread to other parts of the body.
Nice said in its draft guidance that it was pleased to recommend the drug, which is manufactured by Astellas Pharma, for patients who have few other treatment options left.
More top news
New Psychoactive Substances Bill creates a blanket ban on the sale of legal highs, with up to 7 years in jail for selling them.
Pharmaceutical giant Roche is trialling a new type of treatment which could work better than chemotherapy.
Old Labour firebrand Derek Hatton is now locked in a new fight - to rejoin his old party.